eNeura, Inc. Receives FDA Clearance for SpringTMS? Migraine Treatment Device - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
eNeura, Inc. Receives FDA Clearance for SpringTMS? Migraine Treatment Device SpringTMS is the first medical device available to patients in the United States to relieve the pain caused by migraine headaches that are preceded by an aura eNeura to initiate post-market open-label study with leading headache specialists


eNeura, Inc. Receives FDA Clearance for SpringTMS® Migraine Treatment Device

SpringTMS is the first medical device available to patients in the United States to relieve the pain caused by migraine headaches that are preceded by an aura

eNeura to initiate post-market open-label study with leading headache specialists

PR Newswire

BALTIMORE, May 23, 2014 /PRNewswire/ -- eNeura, Inc., a privately held medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SpringTMS® migraine treatment device.  SpringTMS is the first medical device available to patients in the United States for the acute treatment of pain associated with migraine headache with aura.

SpringTMS is a prescription-only device that utilizes single-pulse Transcranial Magnetic Stimulation (sTMS) to induce very mild electrical currents that can depolarize neurons in the brain. This process is thought to interrupt the abnormal hyperactivity associated with migraine. The non-invasive, proprietary device is designed for patient use.  To treat, the device is placed at the back of the head where the push of a button generates a focused magnetic pulse with the intent to eliminate the pain of a migraine headache.

eNeura's first-generation transcranial magnetic stimulation device  (Cerena™) received FDA clearance in December 2013. The FDA reviewed a double-blind, placebo-controlled, randomized clinical study of 201 patients. The study, which took place in 18 U.S. centers, showed that nearly 38 percent of subjects who used sTMS when they had migraine headache pain were pain-free two hours after using the device compared to approximately 17 percent of patients in the control group. After 24 hours, approximately 34 percent of the sTMS users were pain-free compared to only 10 percent in the control group. The treatment did not produce any device-related serious adverse events.

SpringTMS provides the same therapy as the Cerena device but offers improved portability. The initial U.S. availability of SpringTMS will be launched at a select number of U.S. specialist headache centers.

SpringTMS is currently CE Marked in Europe and is available to patients in the United Kingdom for acute treatment of migraine.  The U.K. National Institute for Health and Care Excellence (NICE) recently published positive guidance recommending TMS for acute and preventative treatment of migraine for patients in the U.K.

Professor Peter Goadsby, chair of the British Association for the Study of Headache, and director of the National Headache Centre at King's College Hospital in London, said, "The use of single pulse transcranial magnetic stimulation has given hundreds of patients in the U.K. relief from debilitating migraine without troublesome side effects.  I am sure many migraine sufferers in the U.S. will also experience real benefits from this unique technology."

Dr. David K. Rosen, President and CEO of eNeura, commented, "The FDA clearance of SpringTMS is a significant accomplishment for eNeura and a tremendous validation of our sTMS technology.  We are very confident that SpringTMS will offer tremendous benefit to many migraine sufferers."

Rosen continued, "We are excited to introduce this new treatment to patients in the U.S. through our post-market open-label study with leading headache specialists.  This strategy will ensure we approach the market in a manner that enables the best outcome for patients using our device."

Richard B. Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center at the Albert Einstein College of Medicine, and lead investigator on the Cerena pivotal efficacy study commented, "Many patients with migraine do not get adequate relief from available medications, prefer not to take them and sometimes overuse them.  There is a great need for an effective drug-free acute treatment option for these patients.  The low risk of side effects and the ease of use of the SpringTMS make it a viable option for many of my patients.  I look forward to participating in the post-market observational study for this innovative technology." 

About eNeura
eNeura, Inc., a privately held medical technology company, is pioneering the use of portable, non-invasive single-pulse Transcranial Magnetic Stimulation (sTMS) devices for treatment of migraine.  Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office or on the go.  The eNeura SpringTMS® device is currently CE Marked in Europe and is available in the United Kingdom.  The company's first-generation CerenaTMS™ device received clearance from the FDA for the treatment of migraine preceded by aura in December 2013.  For more information on eNeura and TMS please visit http://www.eneura.com  

Media Contacts:
Claire Sojda / Jason Rando
Tiberend Strategic Advisors, Inc.
212-375-2686 / 2665
csojda@tiberend.com
jrando@tiberend.com

THIS LETTER IS NEITHER AN OFFER TO SELL NOR A SOLICITATION OF AN OFFER TO PURCHASE ANY PARTICULAR SECURITIES.  ANY SUCH OFFER OR SOLICITATION WILL BE MADE ONLY PURSUANT TO THE APPROPRIATE INVESTMENT DOCUMENTS SUPPLIED TO YOU BY THE COMPANY, WHICH QUALIFIES IN THEIR ENTIRETY THE INFORMATION SET FORTH HEREIN

Forward-Looking Statements

Statements made in this newsletter that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the Company's products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements.  As a result, you are cautioned not to put any undue reliance on any forward-looking statement.

SOURCE eNeura, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here